Alcresta Therapeutics’ enzyme derived product, RELiZORB®, is a significant development for patients requiring enteral nutrition who suffer from the devastating consequences of malnutrition and fat malabsorption commonly seen in tube fed patients with Cystic Fibrosis, Gastric Cancers, Pancreatitis, and other serious diseases.
Alcresta were looking for an outsourcing partner with enzyme chemistry experience. A partner who understood enzyme production, purification and immobilization including analytical expertise. A partner who were able to take R&D projects, which involved both chemistry and biochemistry, through to commercial production and product supply. Almac ticked all the boxes for Alcresta. You can read the full article recently showcased in Chemical & Engineering News by clicking here.
